Skip to main content

Significant investments

Typically, building a strategic position begins by investing in a private company with development potential and expands at follow-on financing rounds as well as IPOs.

HBM Healthcare is committed to broad diversification according to the following parameters: private and public companies; development phase; therapeutic area; geography; company size (market capitalisation, valuation). Without the Board of Directors' approval, the acquisition value of an investment may not exceed 10 percent of net assets.

Overview as at 31 December 2019

Shanghai Cathay Biotech
CHF
205
million
CHF
84
million
Y-mAbs Therapeutics
Harmony Biosciences
CHF
63
million
CHF
47
million
SpringWorks Therpeutics
CHF
46
million
Viela Bio
Pacira Pharmaceuticals
CHF
42
million
CHF
37
million
Neurelis